Home
Research
Teaching & Educational
Events
People
 

Mission
The Institute for Cancer Research is a private non-profit institution founded by the Fondazione Piemontese per la Ricerca sul Cancro-Onlus (FPRC) and operated by the Fondazione del Piemonte per l'Oncologia (FPO: a joint venture between the FPRC and the Regione Piemonte). It is the seat of the Department of Oncological Sciences of the University of Torino. Its mission is to make a significant contribution to fight cancer by understanding the basics, and by providing optimal diagnostic and therapeutic services. Both basic research and clinical research are actively performed, placing the Institute at the interface between molecular biology and medicine. The FPRC provides enduring fund raising to complete the Institute’s buildings and to support basic research.

AIRC Special Program in Clinical Molecular Oncology

A translational research aimed at near term benefits to the patients. more


Mettiamo il cancro all'angolo con l'Azalea della Ricerca C'è un giorno, domenica 13 maggio, in cui un fiore si trasforma in una grande forza.

Highlights
 

PNASTargeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.
Proc Natl Acad Sci U S A. 2011 Dec 27.
Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A.


PNAS Small GTPase Rab5 participates in chromosome congression and regulates....
Serio G.,et al, and Bussolino F, Lanzetti L.


Cancer Discovery
A molecularly annotated platform of patient-derived xenografts (xenopatients) identifies HER2 as...
A. Bertotti et al and L. Trusolino


JNCI-Journal of National Cancer Institute
Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer.
Francesca De Bacco, et al Paolo M. Comoglio and Carla Boccaccio


The Journal of Clinical Investigation
Deregulation of the PI3K and KRAS signaling pathways in human cancer...
Federica Di Nicolantonio et al and Alberto Bardelli



Journal of Clinical Investigation
Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.
J Clin Invest. 2012 Apr 9. pii: 58976. doi: 10.1172/JCI58976.
Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, Bussolino F, Serini G, Giraudo E.


Cancer development, progression, and metastasis are highly dependent on angiogenesis. The use of antiangiogenic drugs has been proposed as a novel strategy to interfere with tumor growth, but cancer cells respond by developing strategies to escape these treatments. In particular, animal models show that antiangiogenic drugs currently used in clinical settings reduce tumor tissue oxygenation and trigger molecular events that foster cancer resistance to therapy. Here, we show that semaphorin 3A (S...


EMBO Molecular Medicine
Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform.
EMBO Mol Med. 2012 Mar;4(3):168-70.
Casazza A, Kigel B, Maione F, Capparuccia L, Kessler O, Giraudo E, Mazzone M, Neufeld G, Tamagnone L.


Secreted Semaphorin 3E (Sema3E) promotes cancer cell invasiveness and metastatic spreading. The pro-metastatic activity of Sema3E is due to its proteolytic fragment p61, capable of transactivating the oncogenic tyrosine kinase ErbB2 that associates with the Sema3E receptor PlexinD1 in cancer cells. Here, we show that a mutated, uncleavable variant of Sema3E (Uncl-Sema3E) binds to PlexinD1 like p61-Sema3E, but does not promote the association of PlexinD1 with ErbB2 nor activates the ensuing signa...


 

Next Seminars

Friday 18 May 2012
"Novel roles of B-plexins and GPCRs in tumour cell metastasis"
Prof. Stefan Offermanns
Friday 25 May 2012
"Mechanisms of tumor invasion and evasive resistance to anti-angiogenesis therapy"
Prof. Dr. Amparo Acker-Palmer
Friday 29 June 2012

Prof. Glauco Souza
Friday 13 July 2012
-
Prof. Gail Eckhardt


IRCC Recent Publications

IRCC Reviews

IRCC Salient Publications

Press Room

Italian press


Job Opportunities

       only search on Ircc Site
PeopleIntranetPress RoomHow to Reach
Institute for Cancer Research and Treatment Strada Provinciale 142 km 3,95 10060 Candiolo,Torino-Italy
tel: +390119933111 - fax +390119933225